[go: up one dir, main page]

PE20050232A1 - Metodo y composiciones para tratar la artritis reumatoide - Google Patents

Metodo y composiciones para tratar la artritis reumatoide

Info

Publication number
PE20050232A1
PE20050232A1 PE2004000623A PE2004000623A PE20050232A1 PE 20050232 A1 PE20050232 A1 PE 20050232A1 PE 2004000623 A PE2004000623 A PE 2004000623A PE 2004000623 A PE2004000623 A PE 2004000623A PE 20050232 A1 PE20050232 A1 PE 20050232A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
compositions
rheumatoid arthritis
r8nn
Prior art date
Application number
PE2004000623A
Other languages
English (en)
Inventor
Elizabeth Messersmith
Theodore A Yednock
Ivan Lieberburg
Andrei W Konradi
George Shopp
Michael A Pleiss
Stephen B Freedman
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of PE20050232A1 publication Critical patent/PE20050232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A LA COMBINACION DE CANTIDADES TERAPEUTICAMENTE EFECTIVAS DE METOTREXATO Y UN COMPUESTO DE FORMULA I DONDE R1 ES ALQUILO, ARILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, ALQUILO, CICLOALQUENILO, ENTRE OTROS; R3 ES H, ALQUILO SUSTITUIDO, HETEROARILO, HETEROCICLO, ENTRE OTROS; R5 ES -(CH2)x-Ar-R5N; R5N ES O-Z-NR8R8N, -O-Z-R8NN; R8 Y R8N SON CADA UNO H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R8NN ES HETEROCICLO SUSTITUIDO O NO; Z ES -C(O)-, -SO2-; Ar ES ARILO, HETEROARILO SUSTITUIDO O NO, ARILO SUSTITUIDO; x ES 1-4; Q ES -C(X)NR7-; R7 ES H Y ALQUILO; X ES O, S. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DE N-(TOLUENO-4-SULFONIL)-L-PROLIL-L-4-(4-METILPIPERAZIN-1-ILCARBONILOXI)FENILALANINA; ESTER ISOPROPILICO DE N-(2,4-DIFLUOROBENCENOSULFONIL)-L-(5,5-DIMETIL)TIAPROPIL-L-4-(N,N-DIMETILCARBAMILOXIFENILALANINA Y N-(1-METILPIRAZOL-3-SULFONIL)-L-(5,5-DIMETIL)TIAPROLIL-L-3-CLORO-4-(4-(2-PIRIDIL)PIPERAZIN-1-ILCARBONILOXI)FENILALANINA; ENTRE OTROS. DICHOS COMBINACION ES UTIL COMO TERAPIA EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ENTRE OTRAS
PE2004000623A 2003-06-25 2004-06-25 Metodo y composiciones para tratar la artritis reumatoide PE20050232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48221103P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
PE20050232A1 true PE20050232A1 (es) 2005-04-01

Family

ID=33551975

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000623A PE20050232A1 (es) 2003-06-25 2004-06-25 Metodo y composiciones para tratar la artritis reumatoide

Country Status (12)

Country Link
US (2) US7605166B2 (es)
EP (2) EP1635871A4 (es)
JP (2) JP2007526230A (es)
AR (1) AR044927A1 (es)
AU (2) AU2004251754A1 (es)
CA (2) CA2529873A1 (es)
CL (1) CL2004001621A1 (es)
NZ (1) NZ544367A (es)
PE (1) PE20050232A1 (es)
TW (1) TW200509930A (es)
UY (1) UY28391A1 (es)
WO (2) WO2005000246A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595318B2 (en) * 2004-01-23 2009-09-29 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
BRPI0508814B8 (pt) 2004-03-15 2021-05-25 Ptc Therapeutics Inc derivados de carbolina, bem como uso dos mesmos e composição farmacêutica
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7205310B2 (en) 2004-04-30 2007-04-17 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
EP2298356A3 (en) * 2004-07-08 2011-08-10 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
WO2006065480A2 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
DK1817079T3 (da) 2004-12-02 2008-11-17 Can Fite Biopharma Ltd Behandling af inflammationer
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
MX2007014267A (es) 2005-05-20 2008-02-07 Elan Pharm Inc Derivados de imidazolona fenilamina como antagonistas vla-4.
SG196786A1 (en) 2005-07-08 2014-02-13 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
ZA200803280B (en) * 2005-09-29 2009-11-25 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2201380B1 (en) * 2007-10-22 2016-06-01 Becton Dickinson and Company Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
CN102202676A (zh) * 2008-06-21 2011-09-28 肯贝尔有限责任公司 作为治疗方法的dna-导引的镇痛剂化合物的个体化
SG176840A1 (en) * 2009-06-19 2012-02-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
ES2601819T3 (es) * 2010-03-03 2017-02-16 Teva Pharmaceutical Industries Ltd. Tratamiento de la artritis lúpica usando laquinimod
ES2558556T3 (es) * 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
SI2575870T1 (sl) 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
JP2014530821A (ja) 2011-10-12 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
IN2014DN07224A (es) 2012-02-03 2015-04-24 Basf Se
CA2862865A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf.alpha. therapy
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
IN2014DN07220A (es) 2012-02-03 2015-04-24 Basf Se
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3015069A1 (en) 2014-10-30 2016-05-04 Universitätsklinikum Jena Apparatus for suspended ultrasonography and corresponding method
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
JP6820282B2 (ja) * 2016-02-05 2021-01-27 Ｅａファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物
ES2797298T3 (es) 2016-02-10 2020-12-01 Becton Dickinson France Procedimiento para evaluar la estabilidad de una formulación a base de proteína
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2019172213A1 (ja) * 2018-03-05 2019-09-12 国立大学法人横浜国立大学 ナノ微粒子、及びナノ微粒子の製造方法、並びに抗腫瘍剤
WO2020046964A1 (en) 2018-08-27 2020-03-05 Sydlik Stefanie A Chelator-functionalized glycosaminoglycans
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080503A (en) * 1965-07-02 1967-08-23 Smith & Nephew Substituted acetic acids and a process for their preparation
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
IL133640A0 (en) * 1997-07-31 2001-04-30 Elan Pharm Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
CA2290748A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
DE60036918D1 (de) * 1999-01-22 2007-12-13 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
AU2001234741A1 (en) * 2000-02-04 2001-08-14 Biogen, Inc. Integrin antagonists
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
EP3674322A1 (en) * 2002-02-25 2020-07-01 Biogen MA Inc. Administration of agents for the treatment of inflammation
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Also Published As

Publication number Publication date
US20050065192A1 (en) 2005-03-24
JP2007524626A (ja) 2007-08-30
WO2005000244A2 (en) 2005-01-06
EP1635871A4 (en) 2007-07-18
WO2005000246A2 (en) 2005-01-06
US20050074451A1 (en) 2005-04-07
CA2528723A1 (en) 2005-01-06
AU2004251750A2 (en) 2005-01-06
CL2004001621A1 (es) 2005-03-28
AR044927A1 (es) 2005-10-12
AU2004251754A2 (en) 2005-01-06
JP2007526230A (ja) 2007-09-13
AU2004251754A1 (en) 2005-01-06
EP1635822A4 (en) 2009-06-24
EP1635871A2 (en) 2006-03-22
WO2005000246A3 (en) 2005-11-24
US7605166B2 (en) 2009-10-20
CA2529873A1 (en) 2005-01-06
UY28391A1 (es) 2004-12-31
EP1635822A2 (en) 2006-03-22
TW200509930A (en) 2005-03-16
NZ544367A (en) 2009-12-24
WO2005000244A3 (en) 2005-09-29
AU2004251750A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
PE20050232A1 (es) Metodo y composiciones para tratar la artritis reumatoide
PE20120229A1 (es) Compuestos heterociclicos como inhibidores de proteasa aspartica
CO5611147A2 (es) Derivados de nicotinamida utiles como inhibidores p38
MEP8409A (en) Fused heterocyclic compound
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
EA200600509A1 (ru) Соединения пиримидотиофена
NO20065830L (no) Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer.
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
UA84022C2 (ru) Производные (тио)карбамоилциклогексана как антагонисты d3/d2 рецептора
EA200602067A1 (ru) Производные хиноксалин-2-она, содержащие их средства защиты полезных растений и способ их получения и их применение
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
DE69839739D1 (de) Substituierte 2-(2,6-Dioxopiperidin-3-yl)-Phthalimide und Verfahren zur Verminderung des TNF-Alpha Spiegels
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
TW200503704A (en) N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
NO20060142L (no) Syklisk tertiaer aminforbindelse
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
NO20045351L (no) 1-[(indol-3-yl)karbonyl] piperazin-derivater
EA199801006A1 (ru) Бициклические амины в качестве инсектицидов
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
DE69528189D1 (de) Diazepinoindole inhibitoren von phosphodiesterase iv
MXPA03010436A (es) Amidas biciclicas fusionadas a piridinilo como funguicidas.

Legal Events

Date Code Title Description
FD Application declared void or lapsed